How do I buy ArriVent BioPharma, Inc. Common Stock (AVBP) stock?

Buying ArriVent BioPharma, Inc. Common Stock (AVBP) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "AVBP", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy AVBP by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if AVBP is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

ArriVent BioPharma, Inc. Common Stock (AVBP) Stock

Q: What is the minimum investment for AVBP on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in ArriVent BioPharma, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · AVBP

Trade AVBP

Key stats

Market cap: $827.88M
Price / Earnings ratio: -4.9x
EPS (TTM): -$3.62
Volume: Loading
52-week high: $35.83
52-week low: $11.36

Source: third-party data provider, as of October 17, 2026

Compare with AVBP

Technical indicators

RSI 14: 26.01
MACD 12/26/9: -3.67
EMA 9 of MACD: -2.75
MACD histogram: -0.93
SMA 50: $27.62; Price below SMA 50
EMA 50: $26.11; Price below EMA 50
SMA 200: $27.13; Price below SMA 200
EMA 200: $26.11; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 7 analyst ratings

Strong Sell0

Sell0

Hold0

Buy7

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2025

400M264M132M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-166.3M

Net income

Earnings

No data available

Source: third-party data provider

About ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

SectorHealthcare

IndustryBiotechnology

Employees77

CEODr. Zhengbin Yao Ph.D.

IPO DateJan 25, 2024

HeadquartersNewtown Square, PA

Key Executives

Name	Title	Year Born
Dr. Zhengbin Yao Ph.D.	Co-Founder, Chairman, President & CEO	1966
Mr. Winston Kung M.B.A.	CFO & Treasurer	1976
Ms. Robin LaChapelle M.A.	Co-Founder & COO	1973
Dr. Stuart Lutzker M.D., Ph.D.	Co-Founder, President of Research & Development and Director	1961
Ms. Yang Wang Ph.D.	Chief Technology Officer	—
Dr. James Paul Kastenmayer J.D., Ph.D.	General Counsel & Secretary	1972
Mr. Brent S. Rice	Chief Commercial Officer	1966

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026		+1.5	-0.5	+28.4	+0.9	+13.2	-13.6	+1.4	+0.4	-42.0

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying ArriVent BioPharma, Inc. Common Stock (AVBP) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "AVBP", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy AVBP by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in ArriVent BioPharma, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, ArriVent BioPharma, Inc. Common Stock (AVBP) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track AVBP's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

ArriVent BioPharma, Inc. Common Stock (AVBP) Stock

Key stats

Compare with AVBP

Recent news

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

About ArriVent BioPharma, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade